Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed ...

Business Wire Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 12 Jun 2025 DARMSTADT, Germany Not intended for UK-, US- or Canada ...

UCB and Biogen say their first phase 3 trial of systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, with a second planned.

Get the latest Cabaletta Bio, Inc. (CABA) stock news and headlines to help you in your trading and investing decisions.

Find rheumatology news articles, videos, blogs, books, Continuing Medical Education (CME), meeting coverage, and journal articles.